The Chondroitin Sulfate Market size is estimated at USD 1.32 billion in 2024, and is expected to reach USD 1.56 billion by 2029, growing at a CAGR of 3.36% during the forecast period (2024-2029).
The COVID-19 pandemic disrupted the chondroitin sulfate supply chain, making it difficult for companies to obtain the raw materials they needed to make the product. For instance, according to the article published by BioMed Central in April 2023, the COVID-19 pandemic led to an increase in malnutrition among the most vulnerable children and disrupted food and nutritional API supply chain systems, including chondroitin sulfate APIs. Thus, the pandemic led to shortages of chondroitin sulfate API, which, in turn, led to increased prices, thereby making it difficult for companies to produce and sell chondroitin sulfate-containing products.
Furthermore, the COVID-19 pandemic led to increased research studies on the potential antiviral properties of chondroitin sulfate, which is projected to drive market growth during the forecast period. For instance, a research study published by the Viruses Journal in February 2022 investigated the potential antiviral effects of high-sulfated glycosaminoglycan (GAG) derivatives, including chondroitin sulfate (CS), against coronaviruses, including SARS-CoV-2. Therefore, looking at the overall scenario, the COVID-19 pandemic substantially impacted the market in its initial phases, owing to supply chain disruptions leading to Chondroitin sulfate API shortages and subsequently increased prices. However, increased research into the potential antiviral properties of Chondroitin sulfate and the exploration of its use in new indications after SARS-CoV-2 infection has driven research and investment in this area.
The significant factors contributing to the growth of the chondroitin sulfate market over the forecast period include the rising occurrence of osteoarthritis cases, which are usually treated with chondroitin sulfate, and the increasing applications of chondroitin sulfate in various sectors. For instance, according to the data released by the World Health Organization (WHO) in July 2023, about 73% of people living with osteoarthritis are older than 55 years, and 60% are female.
In addition, the rising prevalence of osteoarthritis of knees and hands coupled with the increasing aging population and obesity is also projected to drive market growth during the forecast period. For instance, according to the data published by the Institute for Health Metrics and Evaluation (IHME) in August 2023, approximately 1 billion people worldwide are projected to suffer from osteoarthritis by the end of 2050, primarily due to the rising obesity cases. Moreover, according to the data released by the World Health Organization (WHO) in July 2023, about 73% of people living with osteoarthritis are older than 55 years, and 60% are female. Therefore, the high prevalence of osteoarthritis in the aging population is projected to drive market growth during the forecast period. Therefore, the high prevalence of osteoarthritis in the aging population is projected to drive market growth during the forecast period.
With an aging global population, joint-related health issues like osteoarthritis are more prevalent. The demand for Chondroitin sulfate as a supplement for joint health is expected to rise as more elderly individuals seek ways to maintain mobility and manage joint discomfort. For instance, the geriatric population in the European Union (EU) is increasing at a rapid pace. For instance, as per the article published by the World Economic Forum in September 2022, more than 30% of the EU population is expected to be 65 or older by 2100. Therefore, the surging geriatric population in different regions of the world is projected to drive market growth during the forecast period.
Actions by key market players to develop the pharmaceutical segment of chondroitin sulfate are expected to boost market growth. For instance, in March 2022, Livisto launched HYALUTIDIN DC, a nutraceutical product for osteochondrosis in dogs and cats in Egypt. HyalutidinDC is an oral solution composed of hyaluronic acid and chondroitin sulfate with high palatability.
Therefore, the increasing incidence of osteoarthritis and strategic activities by market players are anticipated to drive market growth during the forecast period. However, the adverse effects of chondroitin sulfate are a major factor hindering market growth.
For osteoarthritis discomfort, chondroitin sulfate ointments can be used with glucosamine sulfate, shark cartilage, and camphor. Additionally, the growing number of people with osteoarthritis is anticipated to aid in the expansion of the market studied. For instance, according to the data published in September 2021 by the Centers for Disease Control and Prevention (CDC), a person's average lifetime risk for symptomatic osteoarthritis of the knee was almost 50%. Furthermore, according to the statistics of the Arthritis Foundation, in 2022, more than 32.5 million people in the Americas will have osteoarthritis, which will impact nearly half the knees with anterior cruciate ligament (ACL) injuries during a five- to fifteen-year period. According to projections, 78 million Americans will develop osteoarthritis by 2040. Therefore, there are many different medical uses for chondroitin sulfate, and the corresponding market is anticipated to develop dramatically as incidences of osteoarthritis rise.
Moreover, the growing application of chondroitin sulfate and the increasing adoption in pharmaceutical formulations are expected to contribute to the market growth. For instance, in July 2023, Seikagaku Corporation announced that favorable results were obtained in a pivotal study in Japan for SI-449 (SI-449 is a powdered adhesion barrier whose main ingredient is cross-linked chondroitin sulfate), a surgical adhesion barrier in the field of gastroenterological surgery.
Therefore, the segment studied is expected to grow significantly owing to factors such as the increasing burden of osteoarthritis and new product launches in the market.
Osteoarthritis is a chronic disease that affects the knee, hip, shoulder, and hand joints in particular, and the growing prevalence of orthopedic diseases is expected to create the demand for effective treatments, such as chondroitin sulfate, which acts both on the pain and on the slowing down of the degeneration of the articular cartilage. This creates the demand for chondroitin sulfate and boosts the market growth. For instance, according to the statistics released by the CDC in June 2023, an estimated 78.4 million (25.9%) United States adults aged 18 years or older are projected to have doctor-diagnosed arthritis by 2040. Hence, the growing burden of orthopedic diseases is expected to create the demand for chondroitin sulfate, thereby boosting market growth.
The increasing geriatric population is likely to increase the market growth during the forecast period as this population is highly prone to orthopedic diseases. For instance, according to the 2022 statistics published by the United Nations Population Fund, in Canada, about 19% of the population was aged 65 years and above in 2022. Thus, the growing geriatric population is at a high risk of developing musculoskeletal injuries, which raises the demand for chondroitin sulfate products and propels the market growth.
Also, recent product launches in the veterinary sector focusing on improving bone health in pet animals are likely to contribute to market growth. For instance, in March 2021, Dogsnob, a United States-based premium dog supplement brand, launched Mobility Management Soft Chews, which contain chondroitin sulfate, which is formulated to support mobility, relieve pain, maintain bone strength, and promote heart health for puppies, adults, and senior dogs. The product launches to increase the demand for chondroitin sulfate to manufacture the formulation region are expected to boost the growth of the market during the forecast period.
Therefore, the growing burden of orthopedic diseases, such as osteoporosis and arthritis, and the product launches in the country by prominent players are projected to lead to increased competition among the major players. This competition can lead to improved product offerings, new advancements, and pricing competitiveness.
This product will be delivered within 2 business days.
The COVID-19 pandemic disrupted the chondroitin sulfate supply chain, making it difficult for companies to obtain the raw materials they needed to make the product. For instance, according to the article published by BioMed Central in April 2023, the COVID-19 pandemic led to an increase in malnutrition among the most vulnerable children and disrupted food and nutritional API supply chain systems, including chondroitin sulfate APIs. Thus, the pandemic led to shortages of chondroitin sulfate API, which, in turn, led to increased prices, thereby making it difficult for companies to produce and sell chondroitin sulfate-containing products.
Furthermore, the COVID-19 pandemic led to increased research studies on the potential antiviral properties of chondroitin sulfate, which is projected to drive market growth during the forecast period. For instance, a research study published by the Viruses Journal in February 2022 investigated the potential antiviral effects of high-sulfated glycosaminoglycan (GAG) derivatives, including chondroitin sulfate (CS), against coronaviruses, including SARS-CoV-2. Therefore, looking at the overall scenario, the COVID-19 pandemic substantially impacted the market in its initial phases, owing to supply chain disruptions leading to Chondroitin sulfate API shortages and subsequently increased prices. However, increased research into the potential antiviral properties of Chondroitin sulfate and the exploration of its use in new indications after SARS-CoV-2 infection has driven research and investment in this area.
The significant factors contributing to the growth of the chondroitin sulfate market over the forecast period include the rising occurrence of osteoarthritis cases, which are usually treated with chondroitin sulfate, and the increasing applications of chondroitin sulfate in various sectors. For instance, according to the data released by the World Health Organization (WHO) in July 2023, about 73% of people living with osteoarthritis are older than 55 years, and 60% are female.
In addition, the rising prevalence of osteoarthritis of knees and hands coupled with the increasing aging population and obesity is also projected to drive market growth during the forecast period. For instance, according to the data published by the Institute for Health Metrics and Evaluation (IHME) in August 2023, approximately 1 billion people worldwide are projected to suffer from osteoarthritis by the end of 2050, primarily due to the rising obesity cases. Moreover, according to the data released by the World Health Organization (WHO) in July 2023, about 73% of people living with osteoarthritis are older than 55 years, and 60% are female. Therefore, the high prevalence of osteoarthritis in the aging population is projected to drive market growth during the forecast period. Therefore, the high prevalence of osteoarthritis in the aging population is projected to drive market growth during the forecast period.
With an aging global population, joint-related health issues like osteoarthritis are more prevalent. The demand for Chondroitin sulfate as a supplement for joint health is expected to rise as more elderly individuals seek ways to maintain mobility and manage joint discomfort. For instance, the geriatric population in the European Union (EU) is increasing at a rapid pace. For instance, as per the article published by the World Economic Forum in September 2022, more than 30% of the EU population is expected to be 65 or older by 2100. Therefore, the surging geriatric population in different regions of the world is projected to drive market growth during the forecast period.
Actions by key market players to develop the pharmaceutical segment of chondroitin sulfate are expected to boost market growth. For instance, in March 2022, Livisto launched HYALUTIDIN DC, a nutraceutical product for osteochondrosis in dogs and cats in Egypt. HyalutidinDC is an oral solution composed of hyaluronic acid and chondroitin sulfate with high palatability.
Therefore, the increasing incidence of osteoarthritis and strategic activities by market players are anticipated to drive market growth during the forecast period. However, the adverse effects of chondroitin sulfate are a major factor hindering market growth.
Chondroitin Sulfate Market Trends
The Pharmaceutical Segment is Expected to Witness Significant Growth During the Forecast Period
In patients with osteoarthritis, pharmaceutical-grade chondroitin sulfate has frequently been shown to lessen pain and enhance function. It is frequently combined with other substances, such as glucosamine hydrochloride, glucosamine sulfate, manganese ascorbate, and N-acetylglucosamine. It is used in medications to treat acid reflux, interstitial cystitis, Kashin-Beck illness, breast cancer, high cholesterol, muscle soreness after exercise, and psoriasis. Chondroitin sulfate is also taken orally for heart attack, HIV/AIDS, heart disease, osteoporosis, and joint pain.For osteoarthritis discomfort, chondroitin sulfate ointments can be used with glucosamine sulfate, shark cartilage, and camphor. Additionally, the growing number of people with osteoarthritis is anticipated to aid in the expansion of the market studied. For instance, according to the data published in September 2021 by the Centers for Disease Control and Prevention (CDC), a person's average lifetime risk for symptomatic osteoarthritis of the knee was almost 50%. Furthermore, according to the statistics of the Arthritis Foundation, in 2022, more than 32.5 million people in the Americas will have osteoarthritis, which will impact nearly half the knees with anterior cruciate ligament (ACL) injuries during a five- to fifteen-year period. According to projections, 78 million Americans will develop osteoarthritis by 2040. Therefore, there are many different medical uses for chondroitin sulfate, and the corresponding market is anticipated to develop dramatically as incidences of osteoarthritis rise.
Moreover, the growing application of chondroitin sulfate and the increasing adoption in pharmaceutical formulations are expected to contribute to the market growth. For instance, in July 2023, Seikagaku Corporation announced that favorable results were obtained in a pivotal study in Japan for SI-449 (SI-449 is a powdered adhesion barrier whose main ingredient is cross-linked chondroitin sulfate), a surgical adhesion barrier in the field of gastroenterological surgery.
Therefore, the segment studied is expected to grow significantly owing to factors such as the increasing burden of osteoarthritis and new product launches in the market.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
North America is expected to witness significant growth during the forecast period due to factors such as the rise in the prevalence of arthritis and the growing application of chondroitin sulfate. In addition, strategic activities by the market players in the country are also expected to boost market growth.Osteoarthritis is a chronic disease that affects the knee, hip, shoulder, and hand joints in particular, and the growing prevalence of orthopedic diseases is expected to create the demand for effective treatments, such as chondroitin sulfate, which acts both on the pain and on the slowing down of the degeneration of the articular cartilage. This creates the demand for chondroitin sulfate and boosts the market growth. For instance, according to the statistics released by the CDC in June 2023, an estimated 78.4 million (25.9%) United States adults aged 18 years or older are projected to have doctor-diagnosed arthritis by 2040. Hence, the growing burden of orthopedic diseases is expected to create the demand for chondroitin sulfate, thereby boosting market growth.
The increasing geriatric population is likely to increase the market growth during the forecast period as this population is highly prone to orthopedic diseases. For instance, according to the 2022 statistics published by the United Nations Population Fund, in Canada, about 19% of the population was aged 65 years and above in 2022. Thus, the growing geriatric population is at a high risk of developing musculoskeletal injuries, which raises the demand for chondroitin sulfate products and propels the market growth.
Also, recent product launches in the veterinary sector focusing on improving bone health in pet animals are likely to contribute to market growth. For instance, in March 2021, Dogsnob, a United States-based premium dog supplement brand, launched Mobility Management Soft Chews, which contain chondroitin sulfate, which is formulated to support mobility, relieve pain, maintain bone strength, and promote heart health for puppies, adults, and senior dogs. The product launches to increase the demand for chondroitin sulfate to manufacture the formulation region are expected to boost the growth of the market during the forecast period.
Therefore, the growing burden of orthopedic diseases, such as osteoporosis and arthritis, and the product launches in the country by prominent players are projected to lead to increased competition among the major players. This competition can lead to improved product offerings, new advancements, and pricing competitiveness.
Chondroitin Sulfate Industry Overview
The chondroitin sulfate market is fragmented in nature due to the presence of several companies operating globally as well as regionally. Some of the key market players are Lesaffre (Gnosis SpA), Merck KGaA(Sigma-Aldrich Inc.), SARIA International GmbH (Bioiberica S.A.U.), and Rochem International Inc., among others.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - in USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- SARIA International GmbH (Bioiberica S.A.U)
- Rochem International Inc.
- Lesaffre (Gnosis SpA)
- BASIC NUTRITION
- BeiJing Geyuantianrun Bio-tech Co. Ltd
- Merck KGaA (Sigma-Aldrich Inc.)
- Synutra Inc.
- Summit Nutritionals International
- Beloor Bayir
- Chongqing Aoli Biopharmaceutical Co. Ltd
- TSI Group Ltd
Methodology
LOADING...
